Wire · opportunities
Aspen sees Mounjaro Africa sales above $124 million in 2027 - KELO-AM
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 4 September 2026 · Fusion42 review
Aspen Pharmacare expects sales of Eli Lilly’s weight-loss and diabetes drug Mounjaro in Africa to exceed $124 million in the 2027 financial year, driven by demand in South Africa and upcoming launches in Nigeria and Kenya. Aspen is also preparing to launch a generic version of Novo Nordisk’s Ozempic in select markets after patent expiry, with regulatory progress in Canada and emerging markets.
This Wire brief sits within Fusion42's coverage of Health.
◆ ◆ The Wire takeaway
You have a fast-growing African market for weight-loss and diabetes drugs opening now. South African sales leaders like Aspen prove the budget and timeline for new drug launches in markets like Nigeria and Kenya.
◆ Coverage
1 source · 4 Sep 2026
◆ Related on Wire
◆ Topics